EVOKE (semaglutide in early Alzheimer’s)
EVOKE tests oral semaglutide in early Alzheimer’s disease. Existing diabetes/obesity labels are not a dementia indication.
Overview
Phase 3, randomised, placebo-controlled. Cognition outcomes and safety for Alzheimer’s use are still under study. Not for self-directed dementia treatment.
Similar pages
not linked directly; found by shared links- TechnologyBlood Alzheimer biomarkers
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TrialDiranersen / BIIB080 Phase 2
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRONTIER 2 (trontinemab Phase 3)
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentTrontinemab
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- IdeaBlood test before PET or lumbar puncture
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TermMild cognitive impairment
Shares Mild cognitive impairment and the tag dementia-atlas.
- TreatmentDiranersen (BIIB080)
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- PersonAlois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.